You are here

New Angina Indication Approved for Ranolazine

PALO ALTO, Calif., Jan. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ranexa(TM) (ranolazine extended-release tablets).

The approved indication is as follows: Ranexa is indicated for the treatment of chronic angina. Because Ranexa prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other anti-anginal drugs. Ranexa should be used in combination with amlodipine, beta blockers or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than men.

Complete prescribing information for Ranexa, including detailed safety and dosage information, will be available soon at www.cvt.com.

The approval of Ranexa marks the first new pharmaceutical approach to treat angina in more than 20 years in the United States. CV Therapeutics anticipates that Ranexa will be available in pharmacies in late March.

"Patients will now have access to a new angina therapy for the first time in decades," said Louis G. Lange, M.D., Ph.D., CV Therapeutics chairman and chief executive officer. "CV Therapeutics is very proud to have succeeded in bringing this innovative new product to the market, and we look forward to educating cardiology specialists about Ranexa."

To view the FDA release about ranolazine, click here.

Source: CV Therapeutics, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug